Pulmonary Arterial Hypertension-Specific Drug Therapy in COPD Patients with Severe Pulmonary Hypertension and Mild-to-Moderate Airflow Limitation
- PMID: 26492415
- DOI: 10.1159/000441304
Pulmonary Arterial Hypertension-Specific Drug Therapy in COPD Patients with Severe Pulmonary Hypertension and Mild-to-Moderate Airflow Limitation
Abstract
Background: Patients with severe pulmonary hypertension (PH) associated with chronic obstructive pulmonary disease (COPD) present a poor outcome. Specific PH treatment could improve the clinical and hemodynamic status of these patients but may worsen arterial blood gases.
Objectives: Our study retrospectively included 28 patients with severe precapillary PH (mean pulmonary arterial pressure >35 mm Hg) associated with mild-to-moderate COPD [forced expiratory volume in 1 s (FEV1) >50% predicted]. All patients underwent specific pulmonary arterial hypertension (PAH) treatment as mono-, bi- or triple therapy.
Methods: Our single-center study was conducted based on retrospective data of 537 right heart catheterizations (RHCs) performed on patients with COPD from January 2004 to June 2014. An echocardiography, comprehensive blood tests, pulmonary function tests, and a high-resolution computed tomography were performed before the RHCs. All patients underwent RHC with a Swan-Ganz catheter.
Results: Compared to baseline, patients treated with specific PAH drugs showed a significant increase in cardiac index at long term (2.5 ± 0.7 liters/min/m2 at baseline vs. 3.2 ± 0.6 liters/min/m2 at 6/12 months; p = 0.003) as well as a decrease in pulmonary vascular resistance in the long term (8.4 ± 4.2 Wood units at baseline vs. 5 ± 1.7 Wood units at 6/12 months; p = 0.008). There was a slight decrease in arterial oxygen tension (PaO2) after 3 months of treatment (-2.4 ± 7.21 mm Hg; p = 0.066). During a median follow-up of 3 years, 12 patients (42.8%) died (including all causes of death).
Conclusions: This preliminary report suggests that the use of specific PH therapy in severe PH associated with mild-to-moderate COPD can improve pulmonary hemodynamic parameters, with worsening of PaO2, which had no clinical significance and did not lead to specific PAH therapy withdrawal in any patient.
© 2015 S. Karger AG, Basel.
Similar articles
-
Severe pulmonary hypertension associated with COPD: hemodynamic improvement with specific therapy.Respiration. 2015;90(3):220-8. doi: 10.1159/000431380. Epub 2015 Aug 5. Respiration. 2015. PMID: 26277885
-
Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.Arthritis Rheumatol. 2021 Feb;73(2):295-304. doi: 10.1002/art.41512. Epub 2020 Dec 29. Arthritis Rheumatol. 2021. PMID: 32892515
-
Hemodynamic and gas exchange effects of inhaled iloprost in patients with COPD and pulmonary hypertension.Int J Chron Obstruct Pulmon Dis. 2017 Nov 22;12:3353-3360. doi: 10.2147/COPD.S141798. eCollection 2017. Int J Chron Obstruct Pulmon Dis. 2017. PMID: 29200842 Free PMC article. Clinical Trial.
-
Pulmonary hypertension in chronic lung diseases.J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D109-16. doi: 10.1016/j.jacc.2013.10.036. J Am Coll Cardiol. 2013. PMID: 24355635 Review.
-
Evidence-based pharmacologic management of pulmonary arterial hypertension.Clin Ther. 2007 Oct;29(10):2134-53. doi: 10.1016/j.clinthera.2007.10.009. Clin Ther. 2007. PMID: 18042471 Review.
Cited by
-
Pulmonary Vasodilator Therapy in Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (Severe PH-COPD): A Systematic Review and Meta-Analysis.J Cardiovasc Dev Dis. 2023 Dec 16;10(12):498. doi: 10.3390/jcdd10120498. J Cardiovasc Dev Dis. 2023. PMID: 38132665 Free PMC article. Review.
-
Emerging phenotypes of pulmonary hypertension associated with COPD: a field guide.Curr Opin Pulm Med. 2022 Sep 1;28(5):343-351. doi: 10.1097/MCP.0000000000000890. Epub 2022 Jul 16. Curr Opin Pulm Med. 2022. PMID: 35838373 Free PMC article. Review.
-
Clinical application of pulmonary vascular resistance in patients with pulmonary arterial hypertension.J Cardiothorac Surg. 2021 Oct 20;16(1):311. doi: 10.1186/s13019-021-01696-4. J Cardiothorac Surg. 2021. PMID: 34670595 Free PMC article. Review.
-
COPD as an endothelial disorder: endothelial injury linking lesions in the lungs and other organs? (2017 Grover Conference Series).Pulm Circ. 2018 Jan-Mar;8(1):2045894018758528. doi: 10.1177/2045894018758528. Pulm Circ. 2018. PMID: 29468936 Free PMC article.
-
Impact of targeted pulmonary arterial hypertension therapies in severe pulmonary hypertension in chronic lung diseases.ERJ Open Res. 2023 Aug 21;9(4):00027-2023. doi: 10.1183/23120541.00027-2023. eCollection 2023 Jul. ERJ Open Res. 2023. PMID: 37609598 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical